Shilpa Medicare arm secures USFDA orphan drug tag for rare blood cancer biologic

January 28, 2026
Uncategorized

Shilpa Biologicals and mAbTree Biologics received USFDA Orphan Drug Designation for a monoclonal antibody targeting Essential Thrombocythemia and Polycythemia Vera, advancing clinical trials.

Shilpa Medicare arm secures USFDA orphan drug tag for rare blood cancer biologic

Leave a ReplyCancel Reply

FACT slips into ₹68-cr Q3 loss as margins crack despite 65% revenue surge; fertiliser unit turns red

Thyrocare Q3: Profit up nearly 37%, EBITDA surges 47%; diagnostics drive margin expansion

Trade Setup for January 29: Nifty momentum builds on budget optimism amidst Fed, results

Rainbow Children’s Medicare Q3 Results: Revenue up 12% YoY, margin slips on higher expenses

Heritage Foods Q3 revenue up 8%; net profit, margins shrink